Search

Your search keyword '"Milligan, Michael G."' showing total 15 results
Start Over Author "Milligan, Michael G."
15 results on '"Milligan, Michael G."'

4. Observer preference of artificial intelligence‐generated versus clinical prostate contours for ultrasound‐based high dose rate brachytherapy

Author

King, Martin T., primary, Kehayias, Christopher E., additional, Chaunzwa, Tafadzwa, additional, Rosen, Daniel B., additional, Mahal, Amandeep R., additional, Wallburn, Tyler D., additional, Milligan, Michael G., additional, Dyer, M. Aiven, additional, Nguyen, Paul L., additional, Orio, Peter F., additional, Harris, Thomas C., additional, Buzurovic, Ivan, additional, and Guthier, Christian V., additional

Published
2023
Full Text
View/download PDF

5. Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma

Author

Liu, Kevin X., primary, Milligan, Michael G., additional, Schoenfeld, Jonathan D., additional, Tishler, Roy B., additional, Ng, Andrea K., additional, Devlin, Phillip M., additional, Fite, Elliott, additional, Rabinowits, Guilherme, additional, Hanna, Glenn J., additional, Silk, Ann W., additional, Yoon, Charles H., additional, Thakuria, Manisha, additional, and Margalit, Danielle N., additional

Published
2022
Full Text
View/download PDF

9. Target coverage and cardiopulmonary sparing with the updated ESTRO-ACROP contouring guidelines for postmastectomy radiation therapy after breast reconstruction: a treatment planning study using VMAT and proton PBS techniques

Author

Milligan, Michael G., primary, Zieminski, Stephen, additional, Johnson, Andrew, additional, Depauw, Nicolas, additional, Rosado, Nikki, additional, Specht, Michelle C., additional, Liao, Eric C., additional, and Jimenez, Rachel B., additional

Published
2021
Full Text
View/download PDF

12. Treating the SARS‐CoV‐2–positive patient with cancer: A proposal for a pragmatic and transparent ethical process

Author

Perni, Subha, primary, Milligan, Michael G., additional, Saraf, Anurag, additional, Vivenzio, Todd, additional, Marques, Amy, additional, Baker, Meghan A., additional, Kosak, Tara, additional, Bartlett, Sarah, additional, Physic, Michelle A., additional, Batchelder, Monica R., additional, McBride, Sean, additional, Bredfeldt, Jeremy, additional, Cail, Daniel W., additional, Kearney, Meghan C., additional, Whitehouse, Colleen, additional, Orio, Peter, additional, Walsh, Gerard, additional, Haas‐Kogan, Daphne A., additional, and Martin, Neil E., additional

Published
2020
Full Text
View/download PDF

14. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana

Author

Milligan, Michael G., primary, Bigger, Elizabeth, additional, Abramson, Jeremy S., additional, Sohani, Aliyah R., additional, Zola, Musimar, additional, Kayembe, Mukendi K.A., additional, Medhin, Heluf, additional, Suneja, Gita, additional, Lockman, Shahin, additional, Chabner, Bruce A., additional, and Dryden-Peterson, Scott L., additional

Published
2018
Full Text
View/download PDF

15. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.

Author

Milligan, Michael G., Bigger, Elizabeth, Abramson, Jeremy S., Sohani, Aliyah R., Zola, Musimar, Kayembe, Mukendi K.A., Medhin, Heluf, Suneja, Gita, Lockman, Shahin, Chabner, Bruce A., and Dryden-Peterson, Scott L.

Subjects
*HIV status, *HIV infections, *LONGITUDINAL method, *MEDICAL registries, *VINCRISTINE
Abstract

Purpose: Botswana has a high prevalence of HIV infection. Currently, there are few data regarding the sociodemographic factors, clinical characteristics, and outcomes of non-Hodgkin lymphoma (NHL)—an AIDS-defining cancer—in the country. Patients and Methods: This study used a prospective cancer registry to identify patients with a new diagnosis of NHL reporting for specialty cancer care at three hospitals in Botswana between October 2010 and August 2016. Treatment patterns and clinical outcomes were analyzed. Results: One hundred four patients with a new diagnosis of NHL were enrolled in this study, 72% of whom had HIV infection. Compared with patients not infected with HIV, patients infected with HIV were younger (median age, 53.9 v 39.1 years; P =.001) and more likely to present with an aggressive subtype of NHL (65.5% v 84.0%; P =.008). All patients infected with HIV received combined antiretroviral therapy throughout the course of the study, and similar chemotherapeutic regimens were recommended for all patients, regardless of subtype or HIV status (six to eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone; or cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). There was no difference in 1-year mortality among patients not infected with HIV and patients infected with HIV (unadjusted analysis, 52.9% v 37.1%; hazard ratio [HR], 0.73; P =.33; adjusted analysis, HR, 0.57; P =.14). However, when compared with a cohort of patients in the United States matched by subtype, stage, age, sex, and race, patients in Botswana fared worse (1-year mortality, 22.8% v 46.3%; HR, 1.89; P =.001). Conclusion: Among patients with NHL reporting for specialty cancer care in Botswana, there is no association between HIV status and 1-year survival. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results